Previous Close | 9.86 |
Open | 9.71 |
Bid | 9.90 x 900 |
Ask | 9.86 x 800 |
Day's Range | 9.04 - 9.75 |
52 Week Range | 2.09 - 14.84 |
Volume | |
Avg. Volume | 7,061,883 |
Market Cap | 487.858M |
Beta (5Y Monthly) | 0.07 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.54 |
Earnings Date | Mar 26, 2024 - Apr 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 20, 2017 |
1y Target Est | 21.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALT
GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease1 will be presented at the NASH-TAG Conference, which will be held in Park City, UT on January 4-6, 2024. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH2. Det
Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatmentOver 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks Robust reductions in BMI and serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate Altimmune to host conference call tomorrow at 8:30 am EST GAITHERSBURG, Md., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Alti
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, November 7, 2023, at 8:30 am EST GAITHERSBURG, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial resul